News
$21-34 Billion in US Healthcare Costs Due to Antibiotic Resistant Bacteria.

— Infectious Disease Society of America (IDSA)

January 04, 2018

Malvern, PA, January 4, 2018 – VenatoRx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that...

January 03, 2018

Malvern PA., January 3, 2018– VenatoRx Pharmaceuticals, a private clinical-stage pharmaceutical company, announced today that the FDA has granted the company's lead antibiotic program, VNRX-5133, an...

July 27, 2017

VenatoRx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that it has been awarded up to $9.4...

July 25, 2017

VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, today announced that it has raised $42 million in a Series B financing led by Versant Ventures...

September 12, 2016

MALVERN, PA — 09/12/2016 — VenatoRx Pharmaceuticals today announced the appointment of Dr. Michael Diem to the VenatoRx Board of Directors. Dr. Diem is Senior Vice...

July 14, 2015

St. Louis, MO — 14 July 2015— BacterioScan Inc. announced a collaboration with VenatoRx Pharmaceuticals Inc., Malvern, PA, to help reduce the cost and time associated with antimicrobial drug...

January 01, 2015

Dr. Tim Henkel has joined VenatoRx Pharmaceuticals as Chief Medical Officer. Dr. Henkel has spent 20 years in the biopharmaceutical industry developing antibacterial, antifungal, antiviral,...

November 13, 2014

Jim Murphy has joined VenatoRx as Chief Financial Officer.  Jim has over 25 years’ experience as a senior financial executive in public and privately held companies in the life sciences and the media...

Archive: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010